International Journal of Pharmacy and Herbal Technology

e-ISSN: 2583-8962 Vol. 2, Issue 4 (October – December, 2024) pp: (2941-2965)

IJPHT Journal
Papers Having Good Impact

Artificial Intelligence (AI) and Machine Learning (ML) in Drug Design and Development

Vaishnavi Kshirsagar *, Savita D. Sonawane, Sanjay K. Bais
Fabtech College of Pharmacy, Sangola, Solapur, Maharashtra, India
*Corresponding Author: vkshirsagar221@gmail.com

Received Date: November 29, 2024; Published Date: 31 December,2024

Abstract

Artificial intelligence (AI) and machine learning (ML) are altering drug discovery by accelerated and improving certain phases of the research process. Drug discovery has historically been time-consuming and expensive, but AI and ML have made the process quicker by evaluating huge historical data, identifying drug-target interactions, and improving molecular designs with more quality. Machine learning algorithms use virtual screening to find viable drug candidates, minimizing the demand for expensive laboratory testing. AI-driven technologies such as Alpha Fold have made improvements in protein structure prediction, allowing for more accurate targeting and speedier medication development. Furthermore, natural language processing (NLP) algorithms examine scientific research to provide information. Future directions involve the use of AI and quantum technology to improve molecular simulations and improve precision medicine by personalizing therapies to specific genetic profiles. Furthermore, AI will be critical in refining clinical trial designs, predicting patient responses, and providing the safety of medicines, resulting in quicker time to market and improved patient outcomes. As AI and machine learning techniques progress, their impact on drug discovery is projected to increase, revolutionizing the pharmaceutical sector.

Keywords - Artificial Intelligence, Machine Learning, Drug Design, Drug Development, Computational Chemistry.

INTRODUCTION

Drug design

Drug design refers to the imaginative method for designing innovative medicines based on a knowledge of a target within the body.

Artificial Intelligence (AI) involves designing and developing computer systems capable of handling tasks that usually require human intelligence. These tasks include understanding speech, making decisions, solving problems, and recognizing patterns

Machine learning (ML) is a field of artificial intelligence (AI) that involves creating algorithms and models enabling computers to learn from data and make predictions or decisions.

History

The history Intelligent machines in medication design It is distinguished by various distinct eras, each marked by technological advancements and increased integration of AI into the pharmaceutical industry. Here's a detailed timeline:

Early Computational Chemistry Era (1960s–1980s)

Foundations of AI in Drug Design 1960s:

The introduction of QSAR models by Corwin Hansch marked the earliest use of computational methods to predict the natural action of molecules According to the compound's composition. This laid the groundwork for AI applications in drug discovery.

1970s–1980s:

Researchers used Computational Chemistry simulations to model the behaviour of components' relationship to target subjects. These methods allowed for basic AI-driven molecular modelling and docking studies.[1]

Knowledge-Based Systems Era (1990s):

Introduction of Expert Systems

The 1990s saw the development of knowledge-based systems and expert systems, which used AI to simulate the process of deciding capabilities of Professionals in drug discovery.

Key Mechanism

Programs like LUDI and CAVEAT utilized AI to identify pharmacophores (molecular features essential for drug-target interactions) and optimize drug candidates.[2]

Machine Learning and Virtual Screening Era (2000s)

Expansion of AI Capabilities

The 2000s marked a shift toward machine learning (ML), with more sophisticated algorithms like Support vector algorithms (SVMs), choice trees, and random forest modeling are among the techniques used in drug development at different points.

Key Developments

AI-powered virtual screening became a crucial tool, enabling researchers to predict drug-target interactions, identify lead compounds, and optimize chemical structures with greater efficiency.AI algorithms were used to predict ADME properties, they are crucial [3]

For evaluating medicine candidates.

Deep Learning and Big Data Era (2010s)

AI-Driven Drug Discovery

The 2010s saw an explosion in drug development, powered by deeply training and the affordability of huge amounts of information. AI models began to be used for de novo drug design, generating novel chemical structures with specific properties and optimized drug-like features.AI-powered platforms like Atom wise and In silico Medicine utilized deep learning algorithms to perform virtual screening, molecular modelling, and compound optimization.

AlphaFold, developed by DeepMind, made significant advancements in predicting protein structures, which is crucial for understanding how drugs interact with their targets. AI also have a part in automating the examination of large biological and chemical datasets, identifying patterns and correlations that could lead to new drug discoveries.

Modern AI-Driven Drug Discovery Era (2020s and Beyond)

Integrative AI in Pharma

In the 2020s, AI grew to a comprehensive solution for the full pharmaceutical manufacturing pipeline, including targeting and optimization of leads to clinical study preparation.

AI-enabled robotics and automation are being used in laboratories to conduct automated chemical synthesis and streamline the drug development process, reducing timelines and increasing precision.

The evolution of AI in drug design can be summarized as follows:

1960s–1980s: Foundations laid with computational chemistry and basic AI models.
1990s: Rise of knowledge-based systems and expert systems for drug discovery.
2000s: Expansion of AI through machine learning and virtual screening technologies.
2010s: Integration of deep learning and big data for advanced AI-driven drug design.
2020s and Beyond AI becomes a comprehensive tool for end-to-end drug development.[4]

Advantages of AI

Error Minimization

It helps reduce errors and increase accuracy, allowing robots to explore space.

Difficult Exploration

This system is useful in mining, fuel exploration, and ocean exploration.

Daily Application

AI is useful for everyday tasks, such as GPS and Androids, to predict and correct spelling mistakes.

Unlimited Actions

Machinery is not limited by limitations. Without emotion devices can perform tasks greater efficiently and correctly than humans.

Digital Assistants

Artificial Intelligence systems like 'avatar' are being used to reduce human needs, as they are emotionless and can make logical decisions without human emotions.

Repetitive Tasks

People can only perform A single assignment at the same time., Equipment may simultaneously operate and analyse quicker than individuals. Equipment settings, like rate and duration, are able to modified to suit client requirements.

Medical Uses

AI programs enable medical professionals and trainee surgeons to assess patient conditions and analyse Medication-related side effects along with medical hazards, such as artificial surgery simulators.

No Breaks

Machines are programmed to work continuously for long hours without confusion or boredom, unlike humans who can only work 8 hours/day.

Increase technological growth rate

Machine learning programs can be repaired if a mishap occurs in a risky zone, reducing the risk of harm to personnel.

No Risk

Machine learning programs can be repaired if a mishap occurs, reducing the risk of harm to personnel engaged in risky zones.

As an aid

AI technology can serve both children and elders 24/7, providing teaching and learning resources for all. [5,6]

Disadvantages of AI

support vector machines (SVMs)

Computers with artificial intelligence may function like people as well as be dispassionate, permitting machines to do activities extremely effectively and lacking prejudice. There is no enhancement with expertise. AI technology can't be utilized to boost personnel since it can't differentiate between productive and nonworking persons.

No original creativity

Humans have the ability to use their creativity and thoughts, which are not achievable by AI technology.

Unemployment

This technology can lead to large-scale unemployment, affecting human workers' working habits and creativity.

Expensive

AI machines require complex designing, maintenance and repairing, which requires an extended span duration from the R&D separation. Regular software updates and reinstallations and Repair of the equipment also takes both cash and time. [7,8]

Rational of drug design

Data Analysis

Managing Large Datasets: AI and ML can analyse huge amounts of biological and clinical data, finding patterns that are hard for people to see.

Predictive Modelling: These technologies can predict how drug compounds will behave based on past data, helping to identify promising candidates early on.

Finding Drug Targets

Biomarker Discovery: AI can sift through genetic and protein data to find possible targets for new drugs. Pathway Analysis: Machine learning helps to understand complicated biological processes, which can reveal new treatment targets.

Designing New Drugs

De Novo Drug Design: ML algorithms can design new drug candidates by predicting what their molecular structures should look like.

Structure-Activity Relationship (SAR) Modelling: AI examines how chemical structures relate to their biological effects, improving drug candidates based on safety and effectiveness.

Screening Compounds

High-Throughput Screening: AI improves the methods used to quickly evaluate thousands of compounds against specific targets.

Prioritizing Candidates: ML can help choose the best drug candidates based on their chances of success, saving time and money.

Safety Predictions

Adverse Effect Prediction: AI can predict potential side effects and toxicity of drug candidates early, helping to avoid costly failures later.

Risk Assessment: Machine learning evaluates the risks of specific compounds, guiding researchers to safer options.

Optimizing Clinical Trials

Patient Stratification: AI can find the right patient groups for clinical trials by looking at genetic and demographic information, improving trial design.

Predictive Analytics: Machine learning can predict outcomes of clinical trials and identify potential issues, making the process more efficient.

Monitoring After Approval

Real-Time Monitoring: AI can analyze real-world data after drugs are approved to monitor their safety and effectiveness, allowing for quick responses to new safety issues.

Application of Artificial Intelligence

Figure 1: *Application*

Maintaining medical records

The Google Deep Mind health project (created by Google) allows for quick collection, archiving, normalization, and tracing of health information. This project benefits more effective and quicker medical care, and it helps Moor Fields Eye Hospital NHS improve eye therapy.

Treatment plan designing

AI technology is utilized to create efficient treatment strategies for patients facing serious health issues.

Assisting in repetitive tasks

Artificial intelligence (AI) may be utilized for the detection of illnesses or abnormalities, including X-ray radiography, ECHO, and Electrocardiogram. Healthcare Screen is an intellectual aid with analysing and thinking skills.

Health support and medication assistance

Molly, a virtual nurse, and AI Cure are two apps that help Individuals with critical conditions Medication scenarios and clinical trials are essential components of healthcare. Molly offers a friendly voice and appearance, while AI Cure tracks patients and helps them manage their conditions.

Accuracy of medicine

Artificial Intelligence (AI), like Deeper Genetics, has a beneficial effect on genetics or gene improvement by identifying mutations or illness links. Craig Venter's "people Immortality" method analyses individuals' Genomes to identify their physical characteristics. [9]

Classification of Artificial Intelligence (AI)



Figure2: *Classification of Artificial Intelligence*

Types of Artificial Intelligence (Based on Capability)

Weak AI or Artificial Narrow Intelligence (ANI)

This category of AI is created to carry out particular functions like facial recognition, driving cars, playing chess, or managing traffic lights.

Example: Apple's SIRI, which helps with tasks like setting reminders and searching for information.

Artificial General Intelligence (AGI) or Strong AI

This type of AI is capable of performing any cognitive task that a human can accomplish.

It can help solve problems and come up with creative solutions, just like a human.

Super Intelligence (ASI)

This is AI that is much more intelligent than humans in every field, such as art, science, and mathematics. It can range from a computer that is slightly smarter than a human to one that is trillions of times smarter.

AI Classifications Based on Existence (According to AI Scholar Arend Hinze)

Type 1: Reactive Machines

These AI systems are Intended to carry out particular tasks but cannot use past experiences to make future decisions.

Example: IBM's chess program, Deep Blue, which could predict moves but had no memory of past games. Another example is Google's AlphaGo.

Type 2: Limited Memory AI

These systems can leverage previous experiences to influence Decisions for the future, but they don't store these experiences permanently.

Example: Self-driving cars use past observations to make driving decisions, like changing lanes.

Type 3: Theory of Mind

This is a type of AI that understands that people have their own thoughts, intentions, and feelings. However, this type of AI does not yet exist.

Type 4: Self-Awareness

This is AI that is aware of its own existence and can understand and react to its state of being, similar to humans.

Drug development process

The drug development process is a multifaceted journey involving discovery, preclinical testing and regional clinical trial. researchers identify potential drug candidates, conduct laboratory studies to assess safety and efficacy, and progress to human trial. Regulatory agencies evaluate data for approval and post approval ongoing monitoring ensure ongoing safety and effectiveness [10]

Preclinical Research

The journey begins with preclinical research, where potential drug candidates are identified through laboratory investigations. Researchers evaluate these molecules for safety, effectiveness, and mechanisms of action using in vitro tests and animal studies. While regulatory agencies like the FDA do not directly oversee this phase, comprehensive preclinical data are crucial for future regulatory approval

An investigational new drug (IND) application

The shift from preclinical to clinical testing depends on submitting an Investigational New Drug (IND)use. This step is a significant regulatory milestone, as the application details the clinical study's plan, objectives, and preclinical findings. Regulatory authorities carefully review the IND to ensure patient safety and uphold scientific standards before allowing human trials to proceed.[11]

Phase 1 Clinical Trials

As clinical testing begins, Phase I trials utilize a small number of volunteers to establish a drug's safety, dose range, and potential side effects. Regulatory bodies closely review the trial protocols and safety information before granting approval. For the FDA, this stage represents the first direct regulatory involvement, highlighting the critical focus on safety evaluation.

Phase II Clinical Trials

In Phase II, the number of participants increases to further assess the drug's safety and effectiveness. Regulatory oversight becomes more intense, as agencies evaluate the accumulating clinical evidence. Successfully completing this phase allows the transition to larger, more comprehensive Phase III trials.

Phase III Clinical Trials

The series of most intensive tests, Phase III, include thousands of individuals in order to validate the medication's efficacy, examine side effects, and contrast its efficacy with current therapies. Regulatory agencies rigorously review these critical trials, examining the data's reliability to determine the drug's risk-benefit profile. [12]

New Drug Application (NDA)

The NDA is a comprehensive document that compiles all data from preclinical and clinical studies. Regulatory bodies perform thorough evaluations, examining the scientific validity, safety, effectiveness, and manufacturing processes detailed in the application. This stage is a crucial regulatory milestone that decides whether a drug will receive market approval.

Regulatory Decision and Approval

After reviewing the NDA, regulatory agencies decide whether to approve, reject, or request further information. Approval marks the final step, indicating that the drug is ready for market release. If the drug is rejected or if additional information is needed, further adjustments and data submissions are required.[13]

Relevance in Pharmaceutical Research

AI and ML are increasingly Being absorbed into pharmaceutical research to enhance drug discovery, development, and regulatory processes. Below are key applications:

Drug Discovery and Development

Target Identification and Validation

AI and ML Analyze scientific information to identify possible medication sites. And predict their effectiveness and relevance.

Optimization of Drug Design

ML models simulate drug interactions at the molecular level, optimizing chemical structures for higher efficacy and lower side effects

Predicting Drug-Drug Interactions (DDIs)

AI systems can predict DDIs using vast pharmacological datasets, reducing risks in clinical trials and post-market surveillance.

Clinical Trials

Patient Selection and Recruitment

AI systems examine health information and genetic information to select potential participants for clinical studies, make the research more effective and focused.

Monitoring and Outcome Prediction

ML models process patient data in real-time during clinical trials, predicting outcomes and identifying potential adverse reactions early.

Personalized Medicine

AI and ML use genetic and clinical data to create personalized treatments for patients

Regulatory Compliance and Pharmacovigilance

Adverse Event Detection

AI systems analyse post-market data to identify adverse drug reactions quickly, improving pharmacovigilance

Regulatory Document Automation

AI tools streamline the creation and management of regulatory submissions, enhancing efficiency and compliance.

Supply Chain and Manufacturing Optimization

AI and ML optimize pharmaceutical manufacturing processes by predicting maintenance needs and improving production quality control.

These technologies also improve the efficiency of the supply chain by forecasting demand, ensuring availability, and minimizing waste.[14]

Artificial intelligence and Machine learning into pharmaceuticals research

Accelerated Drug Discovery

Target Identification and Validation

AI and machine learning can swiftly analyze enormous volumes of medical information to identify and validate novel therapeutic targets, accelerating the initial drug discovery procedure.

Predictive Modelling

AI and ML can Predicting how substances react to target organisms reduces the demand for costly research in laboratories.

Enhanced Drug Design

De Novo Drug Design

AI algorithms, especially generative models, can design new drug molecules with desired properties, optimizing their effectiveness and minimizing side effects

Optimization of Drug Compounds

ML can be used to refine existing drug molecules, enhancing their efficacy and reducing toxicity by predicting their behaviour in biological systems.

Personalized Medicine

Precision Drug Development

AI can analyse genetic and medical history and conditions to design drugs tailored to individual patients, improving therapeutic outcomes and reducing adverse effects.

Predictive Toxicology and Safety Assessments

Adverse Effect Prediction

AI design can Estimate future side effects and toxicity profiles of compounds early in the manufacturing process, minimizing the likelihood of failure in clinical trials

Safety Testing Automation

AI can automate in silico models for toxicity prediction, complementing or replacing traditional animal testing.

Streamlined Clinical Trials

Patient Recruitment

AI can identify suitable patient populations and optimize trial design, making clinical trials faster and more efficient.

Monitoring and Data Analysis:

Actual tracking and evaluation of experimental study information. Using AI can help detect issues early, ensuring patient safety and improving trial outcomes.

Improved Drug Repurposing

Identification of New Uses for Existing Drugs: AI can analyse existing drug and disease data to identify new therapeutic indications for approved drugs, significantly reducing development time and costs.

Combination Therapies

AI can also explore drug combinations that may be more effective than single treatments, especially for complex diseases like cancer.

Automation and Cost Reduction

Laboratory Automation

AI-driven robotic systems can automate laboratory procedures, speeding up research and reducing human error.

Reduced R&D Costs AI's ability to predict compound behaviour and optimize trial design can significantly lower the costs associated with drug development.

Regulatory Applications

Regulatory Compliance and Monitoring

AI can assist in ensuring compliance with regulatory requirements by automating document analysis and tracking changes in regulations.

Post-Market Surveillance: AI can monitor drug performance in the real world by analysing patient data and adverse event reports, ensuring ongoing safety and effectiveness.[15]

AI and ML Techniques in Drug Discovery

Target Identification and Validation

Artificial intelligence and machine learning technology can use genomic, proteomic, and molecular data to identify and verify biological targets for new medications. These models aid in predicting which proteins or genes may be implicated in disease pathways and hence targets for possible medicines.

Drug Design and Lead Optimization

Artificial intelligence (AI) models assist in the development of novel compounds by identifying their chemical properties and biological activity. This models, like GANs (Generative Adversarial Networks), can generate unique chemical structures that are optimized for specific biological purposes.[16]

Example

Using reinforcement learning algorithms, AI systems can generate compounds with desirable properties like high potency and low toxicity.

Prediction of Drug-Drug Interactions and Toxicity

AI systems such as choice trees and networks of neural networks. can predict adverse drug reactions and interactions by analysing previous clinical data and drug formulation. This lowers the risk of toxicity during drug development.[17]

Example

Machine learning models can predict how a new compound may interact with other drugs or with various biological systems, thereby avoiding side effects.

Clinical Trial Design and Recruitment

AI assists in the optimization of clinical trials by determining appropriate patient populations and predicting patient responses using genetic data. This enhances experiment efficacy and the chances of favourable outcomes.

Example

AI models analyse patient data to design personalized medicine approaches, targeting specific genetic profiles for better outcomes.

Drug Repurposing

AI can help find current drugs that may be helpful in new applications. By analysing biological and chemical databases, ML algorithms can match medications to possible new targets, speeding up the drug development process.

Example

AI platforms like IBM Watson and Benevolent AI have successfully identified existing drugs for treating diseases such as COVID-19.

Virtual Screening and Docking Simulations

AI algorithms, such as convolutional neural networks (CNNs), are used in virtual screening processes to predict how well a drug molecule fits into a target site. This method saves time and resources by narrowing down the list of potential candidates for further testing.[18]

Example

Deep learning design have been used to improve docking accuracy, which is crucial for identifying promising drug candidates in silico.

Pharmacokinetics and Pharmacodynamics (PK/PD) Modelling

AI models are applied to simulate and predict the ADME characters of new medicine. These models help in understanding how drugs behave in the human body and optimizing dosage forms.[18]

Example

AI-based PK/PD models help forecast the time-concentration profile of drugs, ensuring optimal efficacy and safety.

Machine Learning Algorithms

Supervised Learning

Controlled algorithms for learning are developed on labeled information, which means that the input features as well as anticipated result have been determined. The method develops an understanding of the relationship between inputs and results, allowing it to make accurate projections when confronted with fresh, previously unknown information. Some of the most common supervised learning methods are:

Linear Regression for estimating ongoing factors including housing costs, according to characteristics like location and dimension.

Logistic Regression, which is used for binary classification tasks, like determining whether a patient has a specific disease based on medical data.

Decision Trees, which model decisions and outcomes in a tree-like structure, applicable in both classification and regression tasks.

Neural Networks, useful for identifying complex data patterns that other models might miss Supervised learning is mostly used in areas like the recognition of pictures, spam filtering, and medical evaluation.[19]

Unsupervised Learning

Unlike supervised learning, learning without supervision works with data that has no labelled output. The idea is to find similarities., groupings, or relationships Contains the dataset.

Common unsupervised techniques include:

k-Means Clustering, which segments Information in similarity-based groups (e.g., grouping customers based on purchasing behaviour).

Hierarchical Clustering, which builds a nested structure of clusters

Principal Component Analysis (PCA), a approach for minimizing the total amount of factors. in a dataset while retaining its essential information.

Autoencoders, a form of neural network technology utilized for dimensionality reduction and anomaly detection. Applications of unsupervised learning include market segmentation, recommendation engines, and data compression.[20]

Reinforcement Learning

Reinforcement learning focuses on learning an agent to Create a series of selections. within an environment, using rewards and penalties to reinforce desirable actions. This method is often applied in dynamic situations where the agent must maximize cumulative rewards over time.[21]

Artificial Intelligence Discovering drugs



Figure 3: *AI in Drug identification*

AI method in the medical services business have assisted healthcare organizations accelerate their medicinal product development approach. Furthermore, it automates target identification and makes medicine recycling easier by assessing off-target compounds. This leads to faster drug development and fewer repetitive tasks in both the AI and healthcare industries. Leading biopharmaceutical companies are investigating several treatments, including Pfizer's use of IBM Watson, a machine learning-based system, to investigate immuno-oncology medications. IBM Watson is particularly helpful for image and signal processing, as well as prediction. Functional alterations include bladder control, epileptic seizures, and strokes. AI provides a third benefit in healthcare: public health and epidemiology. It can identify viral epidemics of several illnesses, including influenza, dengue fever, tuberculosis, and malaria. AI has predicted the transmission patterns of the Zika virus and the current COVID-19 epidemic.

AI in clinical practice

AI plays an essential role in the healthcare industry by collecting, storing, normalizing, and tracking data. Deep genomics, which recognizes patterns in large amounts of genetic data and medical information, can detect mutations and diseases.

AI in diagnostic and focused genetic treatments

Artificial intelligence (AI) is utilised in healthcare facilities in a range of methods, include grouping pharmacological types for specific individuals as well as establishing acceptable or available modes of administration or therapies.

In accuracy of medicine

The impact of artificial intelligence (AI) on genetic evolution and genomics is beneficial. The Advanced Genomics AI platform is efficient in detecting genomic data and medical records patterns that indicate mutations and correlations that cause diseases. This approach equips healthcare professionals with insights into the cellula changes that occur when genetic variations alter DNA

Data Sources

Datasets Utilized in Drug Discovery

Various datasets are used in drug discovery to uncover new drug applicants, explain biological mechanisms, and optimize manufacturing procedures. These databases usually include chemical and biological data that can be utilized to estimate medication activity, toxicity, and interactions. Following is a discussion of the important datasets often used in this field:

Chemical Libraries

Chemical libraries are collections of chemical substances used to find potential medication concepts. These databases contain structural and physicochemical data, which is critical for evaluating and improving molecules throughout the initial stages of drug development.

Examples

ChEMBL

Is a big database that contains information about how different compounds affect biological activity. that includes information on drug-like small molecules, their properties, and bioactivities.

ZINC Database

A freely accessible resource that offers Financially accessible chemicals for virtual examination, along with their structural and molecular properties.[22]

Biological Databases

Biological databases contain details regarding genes, proteins, pathways, and other biological entities that are essential for analysing disease causes and discovering therapeutic targets. These databases are essential for target validation and mechanism-of-action research in drug discovery.
Examples

GenBank

A comprehensive database of genetic sequences, providing access to nucleotide sequences for a variety of organisms, essential for understanding genetic factors in diseases

Protein Data Bank (PDB)

Contains detailed information on the 3D structures of proteins, which is used for studying protein-drug interactions and developing structure-based drug design approaches.[23]

Pharmacological Databases

Pharmacological databases collect data regarding pharmacological effects, targets, and pharmacokinetics. They are extremely useful for evaluating therapeutic efficacy, adverse effects, and drug-drug interactions.

Examples

Drug Bank: An extensive database containing information on drugs, their chemical and pharmacological properties, as well as their mechanisms of action and drug interactions.
Pharm GKB: Focuses on the relationship between genes, drugs, and diseases, offering information regarding human genetic variables. that influence drug response and pharmacokinetics.[24]

Clinical and Epidemiological Databases

These databases provide details on patient demographics, clinical trial results, and disease occurrence rates. They aid in the design of clinical trials, patient enrollment, as well as customized medication.

Examples

Clinical Trials.gov

A comprehensive registry of clinical trials conducted worldwide, providing data on trial design, patient populations, and outcomes.
SEER (Surveillance, Epidemiology, and End Results Program):Offers cancer statistics and patient demographics, assisting in cancer drug development and epidemiological studies.
These resources highlight the significance of diverse datasets in drug discovery, demonstrating their role in accelerating drug development, optimizing candidate compounds, and ensuring safety and efficacy.

Applications in Drug Design

Virtual Screening

AI and ML techniques have significantly enhanced compound screening in drug design and manufacturing, enhancing both efficiency and accuracy. Here's how they contribute:

Virtual Screening and Drug Discovery

High-Throughput Virtual Screening (HTVS): Traditional compound screening is often time-consuming and resource-heavy. AI/ML models, including deep learning, and random forest algorithms, optimize HTVS by rapidly and accurately predicting the bioactivity of compounds. This helps minimize the number of molecules requiring experimental validation.
Docking Simulations: AI enhances molecular docking by accurately predicting how compounds interact with target proteins. ML models improve scoring functions used in docking, enabling more precise identification of lead compounds.[25]

ADMET Property Prediction

AI/ML design such as support vector machines (SVMs) and neural networks are utilized for estimating drugs' ADMET properties. These models help to identify compounds with poor pharmacokinetics or significant toxicity early on.

Artificial intelligence (AI) systems are capable of predicting the framework of a substance affects its biological effects by combining data from many sources, such as QSAR (Quantitative Structure-Activity Relationship) models. [26]

Lead Compound Optimization

Methods like Generative Adversarial Networks and Reinforcement Learning generate molecular structures with specific features, allowing for faster leads drug development. AI accelerates lead selection and refining by exploring chemical space beyond human capabilities. AI models can also help pick drugs for manufacture and testing based on expected activity, hence reducing experimental costs and time.

Improved Accuracy Through Multi-Omics Data Integration

AI and machine learning models combine genomics, proteomics, and metabolomics with chemical information to Give an entire view of compound interactions, improving prediction accuracy for the effectiveness of therapies and probable adverse reactions. Deep learning techniques excel in detecting complicated patterns in large datasets, resulting in the exact identification of possible medication concepts. [27]

Automation of Chemical Reaction Predictions

AI models, like graph neural networks (GNNs), predict chemical reactions and synthetic pathways for new compounds, assisting chemists in designing drugs with better efficacy and safety profiles. These tools streamline the synthesis process, reducing reliance on traditional trial-and-error methods, thus speeding up drug development.[28]

Accelerated De Novo Drug Design

AI designs such as recurrent neural networks and transformer architectures are employed for de novo drug design, generating new molecular structures with high specificity for target proteins. This capability significantly shortens the early drug development phase, as AI systems quickly propose viable candidates for subsequent testing. Through these AI/ML applications, pharmaceutical companies can streamline the Improve the drug development process, increase screening precision, and bring innovative medicines to the marketplace faster.

De Novo Drug Design

Innovations in developing innovative medication compounds using generative models

De Novo medication Design is a unique strategy to pharmaceutical research that involves developing new medication molecules from starting without changing current ones. This technology uses modern computer tools, such as AI and Machine Learning,to explore massive chemical regions and create compounds with specified features, such as high efficacy and low toxicity. The following sections discuss major aspects and applications of de novo drug design, as well as pertinent sources.

Computational Techniques in De Novo Drug Design

Generative Models

Generative Adversarial Networks, Reinforcement Learning (RL), and Variational Autoencoders are utilized to generate new molecular designs. These models produce compounds that meet specific requirements, such as binding capacity and ADMET, which are critical for drug manufacturing.

Structure-Based Drug Design (SBDD)

This method involves developing therapeutic candidates by targeting the 3D structure of a certain protein. AI models are expecting how various chemical structures would attach to target proteins, facilitating the development of powerful compounds with optimal pharmacological characteristics.[29]

Utilization of Artificial Intelligence and Machine Learning in De Novo Drug Design

Rapid Exploration of Chemical Space

AI and ML models allow researchers to explore millions of possible compounds quickly, far beyond the capabilities of traditional methods. This vast exploration increases the likelihood of identifying promising drug candidates with novel scaffolds or chemical backbones that might not have been considered otherwise.

Multi-Objective Optimization

De novo drug design often involves optimizing multiple properties simultaneously, such as potency, selectivity, and solubility. ML models can optimize these objectives, ensuring the generated compounds are balanced and meet the criteria for further development.[30]

Fragment-Based Drug Design (FBDD)

Assembling Molecules from Fragments: In this approach, AI models use molecular fragments—smaller components of potential drugs—to build new molecules. The fragments are combined in various ways to maximize binding efficiency and drug-likeness. This method is computationally efficient and often results in novel compounds with high biological activity.

Graph Neural Networks (GNNs): GNNs are used to represent molecular fragments and guide the assembly process, ensuring that the designed compounds retain drug-like properties while being synthetically accessible.

AI-Driven Reaction Prediction

Automated Synthesis Pathways: AI models predict the synthetic pathways needed to create the novel compounds designed through de novo methods. This allows for the quick assessment of a compound's synthetic feasibility, reducing time and resources in the lab.

Machine Learning for Reaction Outcome Prediction: By training on large datasets of chemical reactions, AI models can accurately predict the most efficient reactions for synthesizing newly designed compounds, improving the drug development timeline.[31]

Active Learning and Iterative Optimization

Feedback Loops for Model Refinement: In de novo drug design, AI models incorporate experimental data from assays or simulations, dynamically refining the generation process. This active learning approach allows models to Learning from novel knowledge to increase their ability to forecast and develop molecules. Iterative Optimization: Researchers use AI to iteratively optimize molecular features, adjusting properties like solubility, potency, and toxicity to create the best possible drug candidates

Transformer Models for Molecule Generation

Adaptation from Natural Language Processing (NLP): Transformer models, originally developed for NLP, are applied to molecular generation. They encode molecular structures and predict sequences for chemical reactions or the design of new compounds with desirable pharmacological properties. High Precision in Compound Design: These models help generate highly specific compounds tailored for particular therapeutic targets, enhancing the precision and efficiency of the drug design process.

Integrating Multi-Omics Data for Holistic Design

Comprehensive Analysis: Computerized models include information from genomes, proteomics, and metabolic-omics. with chemical information to design compounds that target biological pathways effectively. This holistic approach increases the success rate in identifying viable drug candidates by considering various biological factors.

Enhanced Prediction Accuracy: By combining multi-omics data, AI enhances the prediction accuracy of a compound's efficacy and potential side effects, leading to better-designed molecules.[32]

Structure-Activity Relationship (SAR) Modelling

SAR modelling involves analysing the relationship within the chemical framework of compounds and their Molecular Activities. It's a key aspect in drug discovery and medicinal chemistry, where the aim is to identify which structural features (such as functional groups or molecular fragments) influence the activity of a compound against a biological target.

Overview of Structural Activity Relationship (SAR) Modelling

Goal

To predict the biological activity (e.g., efficacy, toxicity) of Creating novel substances depending on their chemical framework.

Applications

Drug discovery, toxicity prediction, environmental chemistry, and more.

Approach: Identifying patterns in the chemical structure that correlate with biological activity.

Machine Learning (ML) in SAR

Machine learning models are used to predict how effective certain chemical compounds will be based on their features. They learn from examples of compounds that have known structures and how well they work, which helps them make predictions about new product. Key steps in the process include:

1Data Collection and Preparation

Chemical Structure Representation: Molecules are represented using molecular descriptors or fingerprints (e.g., SMILES, molecular graphs).

Activity Data: Bioassay data providing the biological activity of compounds against specific targets.

2Feature Extraction

Molecular Descriptors: The numbers describing architectural characteristics. (e.g., molecular weight, hydrophobicity, electronegativity).

Molecular Fingerprints: Encoded patterns (e.g., ECFP, MACCS) that capture the presence of functional groups or specific molecular fragments

Modelling Techniques

Supervised Learning

Techniques like regression classification (e.g., random forest, SVM) are used when the target (activity) is known.

Deep Learning

Neuronal networks, such as convolutional neural networks and graph neuronal networks (GNNs) can detect complicated designs in chemical structure.

Uncontrolled Learning: Cluster or reduction of dimension (e.g., PCA) helps to identify patterns or group compounds with similar activities

Model Training and Validation

Training Set: Compounds with known activity are utilized for conditioning the model.

Validation Set: A separate set is applied to validate the structural performance and avoid overfitting. Evaluation Metrics: Metrics like mean squared error (MSE), accuracy, ROC-AUC (for classification), and R^2 (for regression) assess model performance.

Interpretation of SAR Models

Identifying structural features that positively or negatively correlate with activity. Visualization tools (e.g., heatmaps, decision trees) can help explain how specific molecular changes influence biological activity.

Benefits of Using ML for SAR Modelling

Efficiency

Rapidly screens large chemical libraries for promising compounds.

Cost Reduction

Reduces the need for extensive experimental testing.

Precision

Models can be fine-tuned to target specific biological pathways or effects.

Challenges in SAR Modelling

Data Quality

Inaccurate or incomplete data can affect model performance.

Interpretability

While deep learning models may be highly accurate, they lacking understanding.

Overfitting

Systems can perform effectively on information used for training but badly on data that is unknown, necessitating careful verification.

Applications

Drug Discovery: Identifying lead compounds with potential therapeutic effects.

Toxicity Prediction: Assessing whether compounds may be harmful based on structural features.

Chemical Design: Designing new compounds with desired biological properties.

SAR modelling using ML is an evolving field with increasing use of advanced algorithms and larger datasets, making it a powerful tool in modern drug discovery and chemical analysis.

Applications in Drug Development



Figure 4: *Applications of AI in drug development*

Case Studies

Case studies on drug design and development explore the journey of discovering, designing, and developing a drug from its inception in the laboratory to its approval and commercialization. These studies highlight challenges, strategies, and breakthroughs encountered during the drug development process. Below are detailed examples.

Case Study: Development of a Novel Cancer Therapy

Background

This case study focuses on developing a targeted cancer treatment, like a tyrosine kinase inhibitor or monoclonal antibody.

Key Aspects

Identifying a molecular target linked to cancer progression. Utilizing computational models for Structure-based medication innovation to create molecules that inhibit this target. Advancing through clinical trial phases (I, II, III) to evaluate safety, efficacy, and dosage levels.[33]

Case Study: Antiviral Drug Design (e.g., COVID-19 Treatment)

Background

Antiviral drug development is critical, especially during pandemics. This case study focuses on the swift development of a COVID-19 treatment.

Key Aspects

Screening of existing drug libraries to identify antiviral activity using high-throughput methods.Refining lead compounds through medicinal chemistry to enhance effectiveness and minimize side effects.Conducting clinical trials through accelerated regulatory pathways, such as emergency use authorizations.[34]

Case Study: Development of Biologics (e.g., Insulin Analogue)

Background

Biologics like insulin analogous have transformed diabetes treatment. This case study explores the development of long-acting insulin analogue.

Key Aspects

Modifying the insulin molecule to alter its absorption and metabolism, creating longer-lasting effects. Testing these Analogue in animal models to evaluate safety and pharmacokinetics. Scaling up production using recombinant DNA technology and cell culture methods. Analysing clinical trial data to compare efficacy and safety profiles with standard insulin.

Case Study: Antimicrobial Innovation and Growth

Background

The rise of Resistance to antibacterial medications is a significant global issue. This case study covers the discovery of a new antibiotic targeting multidrug-resistant bacteria.

Key Aspects

Screening natural products or using synthetic chemistry to create new compounds.Testing these compounds for activity against resistant bacteria and understanding their mechanisms of action.Addressing challenges like toxicity and resistance development during preclinical and clinical trials.[35]

Case Study: Drug Repurposing (e.g., Aspirin for Cardiovascular Disease)

Background

Drug reuse identifies novel therapeutic apply for existing medicines. This case study explores how aspirin, initially an anti-inflammatory, became a treatment for cardiovascular diseases.

Key Aspects

Conducting observational studies showing reduced cardiovascular events in patients using aspirin for other purposes. Running clinical trials to test various dosages and regimens for heart attack and stroke prevention. Assessing side effects and evaluating risk-benefit profiles, particularly related to bleeding risks.

Case Study: Orphan Drug Development (e.g., Cystic Fibrosis Treatment)

Background

Developing treatments for rare diseases presents unique challenges. This case study explores creating a therapy for cystic fibrosis.

Key Aspect

Identifying the genetic mutations responsible for cystic fibrosis. Developing small molecules or gene therapies to target these mutations. Navigating regulatory processes designed for orphan drug development, such as fast-track approvals and market exclusivity.[36]

Successful Implementations of AI/ML in Drug Identification

AI and ML have become essential in drug discovery, enabling faster and more efficient breakthroughs. Below are specific examples where AI/ML significantly impacted drug development:

Case Study: In silico Medicine and the Discovery of DSP-1181

Background

In Silico Medicine, a powered by AI biotechnology startup has cooperated with Sumitomo Dainippon Pharma to develop DSP-1181 for treating obsessive-compulsive disorder (OCD).

AI/ML Involvement

The AI system screened billions of molecules, predicting which compounds would be effective against OCD. The model identified a lead compound in just 46 days, a process that usually takes years.

Outcome

The drug entered clinical trials within a year, showcasing AI's potential to reduce drug development time significantly.

Case Study: Benevolent AI and the Repurposing of Baricitinib for COVID-19

Background

During the COVID-19 pandemic, Benevolent AI used its AI platform to identify existing drugs for COVID-19 treatment.

AI/ML Involvement

The AI analysed biomedical data to identify drug mechanisms, disease pathology, and patient data, leading to the selection of baricitinib as a potential treatment due to its antiviral and anti-inflammatory properties.

Outcome

Baricitinib was promptly integrated into research studies and acquired immediate authorization for use from government agencies such as the FDA.

Case Study: Atom wise and Discovery of Small Molecules for Ebola

Background

Atom wise used its Atom Net platform to discover potential treatments for Ebola.

AI/ML Involvement

Atom Net's deep learning algorithms screened millions of compounds to identify those that could inhibit the Ebola virus.

Outcome

The AI discovered two promising small molecules, speeding up the process of identifying effective drug candidates.[37]

Case Study: GSK's AI-Driven Antibacterial Discovery

Background

GlaxoSmithKline (GSK) collaborated with an AI company to find new antibiotics addressing resistant bacteria.

AI/ML Involvement

AI algorithms analysed bacterial genomic data, identifying vulnerabilities and discovering new molecular scaffolds effective against resistant strains.

Outcome

Multiple antibacterial candidates emerged, showing AI's capability to tackle antibiotic resistance.[38]

Case Study

Recursion Pharmaceuticals and AI Analysis for Rare Diseases

Background

Recursion Pharmaceuticals uses AI to find treatments for rare diseases by analysing phenotypic data

AI/ML Involvement

The AI system screens and analyses cell images to detect disease phenotypes and responses to compounds, enabling rapid discovery.

Outcome

This approach led to the identification of several potential drugs for rare genetic disorders like fibrodysplasia ossificans Progressive (FOP). [39]

Challenges and Limitations

The quality of data and Accessibility

The Accessibility and quality of training Data significantly influences the performance of AI and ML algorithms in medicine identification & manufacturing. However, these statistics include frequently derived from multiple resources, such as preclinical studies, clinical trials, and publicly available databases, resulting in discrepancies and biases. Experimental variability and discrepancies in data collection procedures can lead to incomplete, noisy, or biased datasets, making it challenging to create effective predictive models. Furthermore, the proprietary nature of much pharmaceutical data creates another obstacle; corporations may be reticent to disclose data for confidentiality and intellectual property reasons, limiting access to complete, high-quality datasets. The lack of standardized, annotated, and accessible data poses a hurdle to development and Validation. [40,41]

Challenges and Limitations

Interpretability is a major challenge when using AI and ML in drug design and manufacturing due to the "black-box" design of many advanced structures, like deeply neural networks. These designs are produced very complicated and lack transparency, creating it harder to grasp. how they generate specific predictions or decisions. This lack of clarity is problematic for regulatory approval, as organizations such as the FDA and EMA needed straightforward and clarified. evidence to assess the safety and effectiveness of new drugs. Without transparency, it is difficult to provide the necessary rationale and documentation to regulatory bodies to demonstrate that the AI's decision-making process is reliable, robust, and unbiased. This challenge has significant consequences, as the inability to explain how a model works can delay or even hinder the approval of AI-designed drugs. Therefore, developing interpretable models or methods to explain complex AI systems is essential to build regulatory trust and streamline the drug development process.[42]

Integration into Existing Workflows

Incorporating AI and ML into traditional drug development procedures presents considerable challenges, owing to the disparities in techniques and requirements between conventional and AI-powered approaches. Traditional drug development is mainly based on established laboratory methodologies, specialist knowledge, and experimental validation. Integrating AI models into these workflows frequently necessitates significant infrastructure modifications, including data management systems, computational resources, and specialist skills al. There is also reluctance within businesses due to a lack of experience with AI/ML tools, as well as concerns about their dependability and interpretability in comparison to traditional methods. Furthermore, integrating AI-generated insights into regulatory-compliant procedures presents hurdles, as regulatory authorities frequently seek thorough validation of AI models, which may not correspond with existing drug development standards. Overcoming them. Overcoming these barriers requires not only technical changes, but also cultural reforms inside businesses, highlighting the importance of training, collaboration, and the creation of AI-ready infrastructures. [43,44]

Future Directions

Emerging Technologies

Emerging technologies, particularly quantum computing, have the potential to completely transform drug development by drastically increasing computational capabilities. Quantum computers can analyse massive volumes of data and conduct complex calculations at rates unmatched by traditional computers. This capacity is especially useful for simulating chemical interactions and optimizing drug candidates, which are computationally intensive operations. Quantum computing can improve molecular modelling accuracy, allowing researchers to predict medication interactions with biological targets with more precision and efficiency. [45] Furthermore, advances in quantum machine learning techniques may help to identify novel drug candidates by evaluating enormous datasets and revealing hidden patterns that standard approaches may miss Researchers may be able to speed the medication manufacturing pipeline, reduce expenses, and increase the success rates of new treatments by merging quantum computing with AI and machine learning. As this technology matures, its incorporation into drug discovery workflows may result in important breakthroughs in precision medicine and personalized therapeutic approaches.[45]

Collaborative Approaches

Collaborative Approaches: The future of drug discovery increasingly relies on interdisciplinary collaboration among chemists, biologists, and data scientists. Each discipline brings unique expertise that, when combined, can significantly enhance the drug development process. Chemists contribute their understanding of molecular structures and reactions, while biologists provide insights into biological systems, pathways, and disease mechanisms. Data scientists play a crucial role by developing and applying advanced computational methods, including AI and ML, to analyse large datasets and extract meaningful insights. Collaborative approaches foster innovation by integrating diverse perspectives and knowledge bases, leading to more effective problem-solving and the identification of novel drug candidates. For instance, data scientists can help chemists and biologists interpret complex data from high-throughput screening or genomic studies, guiding experimental design and prioritization of candidates for further testing. Moreover, interdisciplinary teams can enhance the interpretability of AI models, ensuring that the insights generated are relevant and actionable for experimental validation. As drug discovery becomes more complex and data-driven, fostering a culture of collaboration will be essential. Organizations should encourage teamwork through shared goals, cross-training, and Collaboration is the way for bringing off barriers. and promote a holistic approach to drug development. This integrated framework can ultimately lead to more efficient, innovative, and successful drug discovery processes.

Regulatory Frameworks:

Regulatory Frameworks: As AI and ML increasingly influence Making drugs is an essential requirement for comprehensive regulatory frameworks that establish guidelines and standards for evaluating AI-driven processes. Current regulations were primarily designed for traditional drug development methods and do not adequately Addressing the distinct issues presented by artificial intelligence (AI) methods, like inaccurate data, model accessibility, and transparent algorithms. Establishing clear rules would enable governing bodies such as the FDA and EMA analyze the security and effectiveness of Ml-generated medication concepts and guarantee that artificial intelligence systems are strong, dependable, and impartial. This includes developing standards for the validation of AI models, data management practices, and the moral application of AI moral application of AI in clinical settings. Furthermore, these structures should encourage interaction among government organizations and private sector participants in order promote standards of excellence for AI adoption and support the exchange of information.[46]

CONCLUSION

The innovative potential of AI and ML in the field of drug discovery and development is vast, with the ability to alter how new therapies become known, produced, and marketed. These tools make it easier to analyse large datasets, allowing researchers to find hidden patterns, optimize medication designs, and forecast drug interactions with unparalleled accuracy. AI and machine learning have already begun to streamline procedures, cut costs, and enhance drug candidate success rates, thereby considerably improving overall drug development efficiency. Advances in quantum computing, natural language processing, and Modern data visualization are paving the door for advanced algorithms that can help speed up the drug discovery pipeline. To actualize this potential, however, the obstacles that lie ahead must be addressed, including data quality and availability, AI model interpretability, integration into existing workflows, and the construction of strong regulatory frameworks. By overcoming these barriers through multidisciplinary work, respect to moral principles, and the production of detailed instructions, investors may ensure that Artificial Intelligence and ML contribute positively to medicine discovery. As the pharmaceutical industry evolves, adopting these technologies will be crucial for improving patient outcomes and benefiting public health.

REFERENCE

1. Patrick Schneider., William P. Walters., Andrew T. Plowright., Rethinking Drug Design in the Artificial Intelligence, Journal of Nature Review Drug Discovery,2020: 19(5):353–364.
2. Suresh S. Manikiran., Naga Lakshmi Prasanthi., Artificial Intelligence Milestones and Role in Pharma and Healthcare Sector, Journal of Pharma Times, 2019:51(1): 10–15.

3. Mehul Patel., Ramesh Kumar., Machine Learning Approaches for Predicting ADMET Properties in Drug Development, Indian Journal of Pharmaceutical and Health Sciences, 2022:15(1): 45–56.
4. Ravi Desai., Bharat Rao., Quantum Computing and Its Applications in Molecular Simulations for Drug Discovery, Indian Journal of Pharmaceutical and Health Sciences, 2022: 14(3): 178–189.
5. John Smith., A. Brown., Reducing Errors in Automated Systems AI Applications in Space Exploration, Journal of Space Robotics, 2016: 18(4): 250–263.
6. James Wilson., R. Sharma., AI for All Ages Supporting Education and Care with Advanced Technology, Journal of Educational Technology Review, 2018: 16(3):123–138.
7. Sarah Miller., Robert Thompson., The High Cost of AI Development and Maintenance, Financial Technology Journal, 2021: 12(2): 85–99.
8. Thomas Harrison., Suresh Patel., The Economic Burden of AI Integration in Industry, Journal of AI Investment Review, 2019: 8(4): 103–118.
9. Sameer Patel., Laura White., Deep Mind's Impact on Health Data Collection and Management, Journal of Artificial Intelligence in Health, 2019: 15(3): 56–72.
10. Savita D. Sonawane., S. K. Bais., A. N. Gund., Drug Regulatory Affairs, An Overview, International Journal of Pharmacy and Herbal Technology, 2024:2(1): 738–758.
11. Savita D. Sonawane., S. K. Bais., R. U. Dhandore., Quality Control and Quality Assurance: A Review, International Journal of Pharmacy and Herbal Technology, 2024:2(1): 991–1012.
12. Savita D. Sonawane., S. K. Bais., A. N. Gund., Drug Regulatory Affairs, An Overview, International Journal of Pharmacy and Herbal Technology, 2024:2(1): 738–758.
13. Savita D. Sonawane., S. K. Bais., P. D. Kakekar., Assessment of New Drug Delivery System Using Herbal Excipient, International Journal of Pharmacy and Herbal Technology, 2024: 2(1): 1265–1294.
14. Diana Paul., Ganesh Sanap., Suman Shenoy., Artificial Intelligence in Drug Discovery and Development, Drug Discovery Today, 2021: 26(1):80–93.
15. Ankit Gupta., Vikas Kumar., Dinesh K. Patel., Recent Advances in Artificial Intelligence and Machine Learning for Drug Discovery, Indian Journal of Pharmaceutical Education and Research, 2019: 53(4): 546–558.
16. Alexey Kadurin., The Cornucopia of Meaningful Leads Applying Deep Adversarial Autoencoders for New Molecule Development in Oncology, Frontiers in Pharmacology, 2017: 8(1): 689-690.
17. Y. Lee., Artificial Intelligence for Predicting Drug Toxicity in Clinical Development, Journal of Computational and Structural Biotechnology, 2020: 18(2): 1287–1290.
18. Brian J. Schmidt., Artificial Intelligence in Predicting PK/PD Relationships of Drugs, Journal of Pharmacokinetics and Pharmacodynamics, 2019:46(2):97–110.
19. James Smith., Alexandra Doe., Artificial Intelligence in Early-Stage Drug Discovery: Virtual Screening and Predictive Modelling, Indian Journal of Pharmaceutical Health Science, 2022; 14(3):123-134.
20. Rui Xu., Donald Wunsch., Survey of Clustering Algorithms, Journal of Institute of Electrical and Electronics Engineers Transactions on Neural Networks, 2005: 16(3): 645–678.

21. Sanjay Arora., Prashanth Reddy., S. Balasubramanian., Daniel Probst., Artificial Intelligence in Drug Discovery: A Regulatory Perspective,Nature Biotechnology, 2021:39(5):138-142.
22. Sundhwan Kim., Public Chemical Substance and Compound Databases, Journal of Nucleic Acids Research, 2016:44(1): 1202–1213.
23. Gaulton A., Chemical Biology A Large-Scale Bioactivity Database for Drug Discovery, Journal of Nucleic Acids Research, 2012: 40(1):1100–1107.
24. David S. Wishart., Drug Bank 5.0 A Major Update to the Drug Bank Database, Journal of Nucleic Acids Research, 2018: 46(1): 1074–1082.
25. James Smith., Alexandra Doe., Artificial Intelligence in Early-Stage Drug Discovery: Virtual Screening and Predictive Modelling, Indian Journal of Pharmaceutical Health Science, 2022: 14(3):123–134.
26. Alex Zhavoronkov., Deep Learning Enables Rapid Identification of Potent Discoidin Domain Receptor 1Kinase Inhibitor, Nature Biotechnology, 2020:38(8):1039–1047.
27. Xiaohong Zeng., Multi-Omic Data Integration in Drug Discovery Advances and Challenges, Trends in Pharmacological Sciences, 2021: 42(6):456–469.
28. Sean Ekins., In Silico Drug Discovery Computational Methods and Practical Applications, Pharmacology and Therapeutics, 2019: 20(5):102-130.
29. O.Mendez-Lucio., Bastien Baillif., De Novo Drug Design with Artificial Intelligence: A Focused Review on Generative Models, Journal of Frontiers in Drug Discovery, 2020: 1(6):4-10.
30. Alex Zhavoronkov., Deep Learning Enables Rapid Identification of Potent Discoidin Domain Receptor 1 Kinase Inhibitor, Journal of Nature Biotechnology, 2020: 38(8):1038–1040.
31. A. Haslehurst., Phenotypic Drug Discovery Facilitated by Artificial Intelligence in Rare Diseases, Journal of Trends in Pharmacological Sciences, 2021: 42(3):174–189.
32. Phillippe Schwaller., Predicting Chemical Reactions Using Neural Networks, Journal of Nature, 2020: 5(3):237–241.
33. Aniket Gupta., Generative Recurrent Networks for De Novo Drug Design, Journal of Molecular Informatics, 2018: 37(2):17–25.
34. Slaoui M., Lauer W., Accelerated Clinical Trials for COVID-19 Vaccines and Therapies. Journal of Nature Reviews Drug Discovery,2020:19(5): 306-312
35. Alex Zhavoronkov., Artificial Intelligence for Drug Discovery, Biomarker Development, and Generation of Novel Chemistry, Journal of ACS Medicinal Chemistry Letters, 2019: 10(10):158–165.
36. Jonathan M. Stokes., A Deep Learning Approach to Antibiotic Discovery, Journal of Cell, 2020:180(4):688–702.
37. Jonathan H. Beigel., Remdesivir for the Treatment of COVID-19-Final Report, New England Journal of Medicine, 2020:3(5):1813–1826.
38. Levine A., Neill J.,Artificial Intelligence and Machine Learning in the Fight Against Antibiotic Resistance,Journal of Nature Review Microbiology, 2019: 17(5):269-276.
39. Alex Zhavoronkov., Deep Learning Enables Rapid Identification of Potent DDR1 Kinase Inhibitors, Journal of Nature Biotechnology, 2019: 37(9):1038–1040.
40. Manish Verma., Pranab Sarma., Sanjay Kumar., Artificial Intelligence Applications in the Fight Against COVID-19: Present Status and Future Prospects, Indian Journal of Pharmacology, 2020: 52(5):389–397.

41. Sanjay Kumar., Rajesh Singh., Ravi Kaushik., Drug Discovery in India Challenges and Opportunities, Indian Journal of Experimental Biology, 2018:56(1):11–19.
42. J.Vamathevan., Applications of Machine Learning in Drug Discovery and Development, Journal of Nature Reviews Drug Discovery, 2019:1(8):463–477.
43. Joubert D., Ochoa D., Challenges of Integrating Artificial Intelligence in Pharmaceutical Research & Development, Journal of Artificial Intelligence Health Care,2020: 2(4), 235–244.
44. Andreas Esteva., Alexandre Robicquet., Bharat Ramsundar., A Guide to Deep Learning in Healthcare, Journal of Nature Medicine, 2019:2(5):24–29.
45. Yuan Cao., Javier Romero., Alan Aspuru-Guzik., Potential of Quantum Computing for Drug Discovery, Journal of Nature Reviews Drug Discovery, 2018:17(7):471–472.
46. Sanjay Arora., Pradeep Reddy., Sathyanarayanan Balasubramanian., Daniel Probst., Artificial Intelligence in Drug Discovery a Regulatory Perspective, Journal of Nature Biotechnology, 2021:3(9):138–142.